Report Detail
Global Focal Segmental Glomerulosclerosis (FSGS) Market Insights, Forecast to 2025
- RnM2423782 |
- 11 June, 2019 |
- Global |
- 111 Pages |
- QYResearch |
- Pharma & Healthcare
Focal Segmental Glomerulosclerosis (FSGS) is a cause of nephrotic syndrome in children and adolescents, as well as a leading cause of kidney failure in adults.
The global Focal Segmental Glomerulosclerosis (FSGS) market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Focal Segmental Glomerulosclerosis (FSGS) market based on company, product type, end user and key regions.
This report studies the global market size of Focal Segmental Glomerulosclerosis (FSGS) in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Focal Segmental Glomerulosclerosis (FSGS) in these regions.
This research report categorizes the global Focal Segmental Glomerulosclerosis (FSGS) market by top players/brands, region, type and end user. This report also studies the global Focal Segmental Glomerulosclerosis (FSGS) market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Variant Pharmaceuticals
ChemoCentryx
Retrophin
Novartis
Pfizer
AstraZeneca
Sanofi
GlaxoSmithKline
Teva Pharmaceutical
Market size by Product
Primary Focal Segmental Glomerulosclerosis
Secondary Focal Segmental Glomerulosclerosis
Market size by End User
Hospitals
Ambulatory Surgical Centers
Specialty Clinics
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Focal Segmental Glomerulosclerosis (FSGS) market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Focal Segmental Glomerulosclerosis (FSGS) market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Focal Segmental Glomerulosclerosis (FSGS) companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Focal Segmental Glomerulosclerosis (FSGS) submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Focal Segmental Glomerulosclerosis (FSGS) are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (Kg). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Focal Segmental Glomerulosclerosis (FSGS) market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Study Coverage
- 1.1 Focal Segmental Glomerulosclerosis (FSGS) Product
- 1.2 Market Segments
- 1.3 Key Manufacturers Covered
- 1.4 Market by Type
- 1.4.1 Global Focal Segmental Glomerulosclerosis (FSGS) Market Size Growth Rate by Product
- 1.4.2 Primary Focal Segmental Glomerulosclerosis
- 1.4.3 Secondary Focal Segmental Glomerulosclerosis
- 1.5 Market by End User
- 1.5.1 Global Focal Segmental Glomerulosclerosis (FSGS) Market Size Growth Rate by End User
- 1.5.2 Hospitals
- 1.5.3 Ambulatory Surgical Centers
- 1.5.4 Specialty Clinics
- 1.6 Study Objectives
- 1.7 Years Considered
2 Executive Summary
- 2.1 Global Focal Segmental Glomerulosclerosis (FSGS) Market Size
- 2.1.1 Global Focal Segmental Glomerulosclerosis (FSGS) Revenue 2014-2025
- 2.1.2 Global Focal Segmental Glomerulosclerosis (FSGS) Sales 2014-2025
- 2.2 Focal Segmental Glomerulosclerosis (FSGS) Growth Rate by Regions
- 2.2.1 Global Focal Segmental Glomerulosclerosis (FSGS) Sales by Regions
- 2.2.2 Global Focal Segmental Glomerulosclerosis (FSGS) Revenue by Regions
3 Breakdown Data by Manufacturers
- 3.1 Focal Segmental Glomerulosclerosis (FSGS) Sales by Manufacturers
- 3.1.1 Focal Segmental Glomerulosclerosis (FSGS) Sales by Manufacturers
- 3.1.2 Focal Segmental Glomerulosclerosis (FSGS) Sales Market Share by Manufacturers
- 3.1.3 Global Focal Segmental Glomerulosclerosis (FSGS) Market Concentration Ratio (CR5 and HHI)
- 3.2 Focal Segmental Glomerulosclerosis (FSGS) Revenue by Manufacturers
- 3.2.1 Focal Segmental Glomerulosclerosis (FSGS) Revenue by Manufacturers (2014-2019)
- 3.2.2 Focal Segmental Glomerulosclerosis (FSGS) Revenue Share by Manufacturers (2014-2019)
- 3.3 Focal Segmental Glomerulosclerosis (FSGS) Price by Manufacturers
- 3.4 Focal Segmental Glomerulosclerosis (FSGS) Manufacturing Base Distribution, Product Types
- 3.4.1 Focal Segmental Glomerulosclerosis (FSGS) Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers Focal Segmental Glomerulosclerosis (FSGS) Product Type
- 3.4.3 Date of International Manufacturers Enter into Focal Segmental Glomerulosclerosis (FSGS) Market
- 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
- 4.1 Global Focal Segmental Glomerulosclerosis (FSGS) Sales by Product
- 4.2 Global Focal Segmental Glomerulosclerosis (FSGS) Revenue by Product
- 4.3 Focal Segmental Glomerulosclerosis (FSGS) Price by Product
5 Breakdown Data by End User
- 5.1 Overview
- 5.2 Global Focal Segmental Glomerulosclerosis (FSGS) Breakdown Data by End User
6 North America
- 6.1 North America Focal Segmental Glomerulosclerosis (FSGS) by Countries
- 6.1.1 North America Focal Segmental Glomerulosclerosis (FSGS) Sales by Countries
- 6.1.2 North America Focal Segmental Glomerulosclerosis (FSGS) Revenue by Countries
- 6.1.3 United States
- 6.1.4 Canada
- 6.1.5 Mexico
- 6.2 North America Focal Segmental Glomerulosclerosis (FSGS) by Product
- 6.3 North America Focal Segmental Glomerulosclerosis (FSGS) by End User
7 Europe
- 7.1 Europe Focal Segmental Glomerulosclerosis (FSGS) by Countries
- 7.1.1 Europe Focal Segmental Glomerulosclerosis (FSGS) Sales by Countries
- 7.1.2 Europe Focal Segmental Glomerulosclerosis (FSGS) Revenue by Countries
- 7.1.3 Germany
- 7.1.4 France
- 7.1.5 UK
- 7.1.6 Italy
- 7.1.7 Russia
- 7.2 Europe Focal Segmental Glomerulosclerosis (FSGS) by Product
- 7.3 Europe Focal Segmental Glomerulosclerosis (FSGS) by End User
8 Asia Pacific
- 8.1 Asia Pacific Focal Segmental Glomerulosclerosis (FSGS) by Countries
- 8.1.1 Asia Pacific Focal Segmental Glomerulosclerosis (FSGS) Sales by Countries
- 8.1.2 Asia Pacific Focal Segmental Glomerulosclerosis (FSGS) Revenue by Countries
- 8.1.3 China
- 8.1.4 Japan
- 8.1.5 Korea
- 8.1.6 India
- 8.1.7 Australia
- 8.1.8 Indonesia
- 8.1.9 Malaysia
- 8.1.10 Philippines
- 8.1.11 Thailand
- 8.1.12 Vietnam
- 8.1.13 Singapore
- 8.2 Asia Pacific Focal Segmental Glomerulosclerosis (FSGS) by Product
- 8.3 Asia Pacific Focal Segmental Glomerulosclerosis (FSGS) by End User
9 Central & South America
- 9.1 Central & South America Focal Segmental Glomerulosclerosis (FSGS) by Countries
- 9.1.1 Central & South America Focal Segmental Glomerulosclerosis (FSGS) Sales by Countries
- 9.1.2 Central & South America Focal Segmental Glomerulosclerosis (FSGS) Revenue by Countries
- 9.1.3 Brazil
- 9.2 Central & South America Focal Segmental Glomerulosclerosis (FSGS) by Product
- 9.3 Central & South America Focal Segmental Glomerulosclerosis (FSGS) by End User
10 Middle East and Africa
- 10.1 Middle East and Africa Focal Segmental Glomerulosclerosis (FSGS) by Countries
- 10.1.1 Middle East and Africa Focal Segmental Glomerulosclerosis (FSGS) Sales by Countries
- 10.1.2 Middle East and Africa Focal Segmental Glomerulosclerosis (FSGS) Revenue by Countries
- 10.1.3 GCC Countries
- 10.1.4 Turkey
- 10.1.5 Egypt
- 10.1.6 South Africa
- 10.2 Middle East and Africa Focal Segmental Glomerulosclerosis (FSGS) by Product
- 10.3 Middle East and Africa Focal Segmental Glomerulosclerosis (FSGS) by End User
11 Company Profiles
- 11.1 Variant Pharmaceuticals
- 11.1.1 Variant Pharmaceuticals Company Details
- 11.1.2 Company Business Overview
- 11.1.3 Variant Pharmaceuticals Focal Segmental Glomerulosclerosis (FSGS) Sales, Revenue and Gross Margin (2014-2019)
- 11.1.4 Variant Pharmaceuticals Focal Segmental Glomerulosclerosis (FSGS) Products Offered
- 11.1.5 Variant Pharmaceuticals Recent Development
- 11.2 ChemoCentryx
- 11.2.1 ChemoCentryx Company Details
- 11.2.2 Company Business Overview
- 11.2.3 ChemoCentryx Focal Segmental Glomerulosclerosis (FSGS) Sales, Revenue and Gross Margin (2014-2019)
- 11.2.4 ChemoCentryx Focal Segmental Glomerulosclerosis (FSGS) Products Offered
- 11.2.5 ChemoCentryx Recent Development
- 11.3 Retrophin
- 11.3.1 Retrophin Company Details
- 11.3.2 Company Business Overview
- 11.3.3 Retrophin Focal Segmental Glomerulosclerosis (FSGS) Sales, Revenue and Gross Margin (2014-2019)
- 11.3.4 Retrophin Focal Segmental Glomerulosclerosis (FSGS) Products Offered
- 11.3.5 Retrophin Recent Development
- 11.4 Novartis
- 11.4.1 Novartis Company Details
- 11.4.2 Company Business Overview
- 11.4.3 Novartis Focal Segmental Glomerulosclerosis (FSGS) Sales, Revenue and Gross Margin (2014-2019)
- 11.4.4 Novartis Focal Segmental Glomerulosclerosis (FSGS) Products Offered
- 11.4.5 Novartis Recent Development
- 11.5 Pfizer
- 11.5.1 Pfizer Company Details
- 11.5.2 Company Business Overview
- 11.5.3 Pfizer Focal Segmental Glomerulosclerosis (FSGS) Sales, Revenue and Gross Margin (2014-2019)
- 11.5.4 Pfizer Focal Segmental Glomerulosclerosis (FSGS) Products Offered
- 11.5.5 Pfizer Recent Development
- 11.6 AstraZeneca
- 11.6.1 AstraZeneca Company Details
- 11.6.2 Company Business Overview
- 11.6.3 AstraZeneca Focal Segmental Glomerulosclerosis (FSGS) Sales, Revenue and Gross Margin (2014-2019)
- 11.6.4 AstraZeneca Focal Segmental Glomerulosclerosis (FSGS) Products Offered
- 11.6.5 AstraZeneca Recent Development
- 11.7 Sanofi
- 11.7.1 Sanofi Company Details
- 11.7.2 Company Business Overview
- 11.7.3 Sanofi Focal Segmental Glomerulosclerosis (FSGS) Sales, Revenue and Gross Margin (2014-2019)
- 11.7.4 Sanofi Focal Segmental Glomerulosclerosis (FSGS) Products Offered
- 11.7.5 Sanofi Recent Development
- 11.8 GlaxoSmithKline
- 11.8.1 GlaxoSmithKline Company Details
- 11.8.2 Company Business Overview
- 11.8.3 GlaxoSmithKline Focal Segmental Glomerulosclerosis (FSGS) Sales, Revenue and Gross Margin (2014-2019)
- 11.8.4 GlaxoSmithKline Focal Segmental Glomerulosclerosis (FSGS) Products Offered
- 11.8.5 GlaxoSmithKline Recent Development
- 11.9 Teva Pharmaceutical
- 11.9.1 Teva Pharmaceutical Company Details
- 11.9.2 Company Business Overview
- 11.9.3 Teva Pharmaceutical Focal Segmental Glomerulosclerosis (FSGS) Sales, Revenue and Gross Margin (2014-2019)
- 11.9.4 Teva Pharmaceutical Focal Segmental Glomerulosclerosis (FSGS) Products Offered
- 11.9.5 Teva Pharmaceutical Recent Development
12 Future Forecast
- 12.1 Focal Segmental Glomerulosclerosis (FSGS) Market Forecast by Regions
- 12.1.1 Global Focal Segmental Glomerulosclerosis (FSGS) Sales Forecast by Regions 2019-2025
- 12.1.2 Global Focal Segmental Glomerulosclerosis (FSGS) Revenue Forecast by Regions 2019-2025
- 12.2 Focal Segmental Glomerulosclerosis (FSGS) Market Forecast by Product
- 12.2.1 Global Focal Segmental Glomerulosclerosis (FSGS) Sales Forecast by Product 2019-2025
- 12.2.2 Global Focal Segmental Glomerulosclerosis (FSGS) Revenue Forecast by Product 2019-2025
- 12.3 Focal Segmental Glomerulosclerosis (FSGS) Market Forecast by End User
- 12.4 North America Focal Segmental Glomerulosclerosis (FSGS) Forecast
- 12.5 Europe Focal Segmental Glomerulosclerosis (FSGS) Forecast
- 12.6 Asia Pacific Focal Segmental Glomerulosclerosis (FSGS) Forecast
- 12.7 Central & South America Focal Segmental Glomerulosclerosis (FSGS) Forecast
- 12.8 Middle East and Africa Focal Segmental Glomerulosclerosis (FSGS) Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
- 13.1 Market Opportunities and Drivers
- 13.2 Market Challenges
- 13.3 Market Risks/Restraints
- 13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
- 14.1 Value Chain Analysis
- 14.2 Focal Segmental Glomerulosclerosis (FSGS) Customers
- 14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
- 16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
- 16.2 Author Details
Summary:
Get latest Market Research Reports on Focal Segmental Glomerulosclerosis (FSGS) . Industry analysis & Market Report on Focal Segmental Glomerulosclerosis (FSGS) is a syndicated market report, published as Global Focal Segmental Glomerulosclerosis (FSGS) Market Insights, Forecast to 2025. It is complete Research Study and Industry Analysis of Focal Segmental Glomerulosclerosis (FSGS) market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
